Fig. 3From: Management of retinitis pigmentosa by Wharton’s jelly derived mesenchymal stem cells: preliminary clinical resultsa, b Visual field changes in the WJ-MSC treatment (Table 1, patient no. 2: left eye). a: before the application, b: 6 months later after the applicationBack to article page